Newsroom | Co-Diagnostics, Inc.

Newsroom

Month Year

Media Resources

Mar 21, 2023

Co-Diagnostics, Inc. to CEO to Deliver Keynote Address at 2023 MarketsandMarkets Conference in London, England

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Mar 17, 2023

Co-Diagnostics, Inc. to Host Booth at 10th Gene Quantification Event in Munich, Germany, March 20-22

Chair of Company's SAB, Dr. Carl Wittwer, to present on at-home PCR testing SALT LAKE CITY, March 17, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a...
Mar 16, 2023

Co-Diagnostics, Inc. Reports Full Year 2022 Financial Results

Full-year Results Impacted by Lower Demand for COVID-19 Testing Announced Initiation of Clinical Evaluations for Co-Dx PCR Home™ Platform SALT LAKE CITY, March 16, 2023 /PRNewswire/ --...
Mar 9, 2023

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth...
Mar 2, 2023

Co-Diagnostics, Inc. to Present and Host Booth at TRI-CON in San Diego, CA, March 6-8

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Feb 28, 2023

Co-Diagnostics, Inc. to Host Booth at 89th Annual AMCA Conference in Reno, NV on Feb 28-March 3

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
- Photos 1
Feb 22, 2023

Co-Diagnostics, Inc. Initiates Clinical Evaluations for its At-Home and Point-of-Care Co-Dx PCR Home™ Platform

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced...
- Photos 1
Feb 2, 2023

Co-Diagnostics, Inc. to Host Booth at Medlab Middle East 2023 in Dubai on February 6-9

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Jan 24, 2023

Co-Diagnostics, Inc. Commemorates Third Anniversary of the Completion of its First COVID-19 Test Design

Designed using the Company's proprietary platform, initial test design remains effective detection tool even after three years of variants and more than 33 million sold worldwide; Company also...
- Photos 1
Jan 5, 2023

Co-Diagnostics, Inc. to Host Booth at CES 2023 January 5-8

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Nov 30, 2022

Co-Diagnostics, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Nov 14, 2022

Co-Diagnostics, Inc. to Host Booth at MEDICA 2022 Trade Fair in Düsseldorf, Germany

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Nov 10, 2022

Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter results SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ --...
Nov 3, 2022

Co-Diagnostics, Inc. to Host Booth at AMP This Week in Phoenix, AZ

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Nov 1, 2022

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Oct 27, 2022

CO-DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third...
Oct 26, 2022

Co-Diagnostics, Inc. to Host Booth at Medlab Africa on Oct 26-28 in South Africa

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Oct 19, 2022

Co-Diagnostics, Inc. to Host Booths at Conferences in Washington, D.C. and Bangkok, Thailand

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Sep 14, 2022

Co-Diagnostics, Inc. to Sponsor, Present, and Host Booth at 66th Annual CARPHA Conference on Sept 15-17 in Jamaica

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Sep 12, 2022

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Aug 31, 2022

Co-Diagnostics, Inc. to Host Booth at Medical Fair Asia 2022 in Singapore on Aug 31-Sep 2

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or Co-Dx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Aug 22, 2022

Co-Diagnostics, Inc. to Present at 14th Next Generation Dx Summit in Washington, D.C.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Aug 11, 2022

Co-Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:...
Aug 2, 2022

/C O R R E C T I O N -- Co-Diagnostics/

In the news release, CO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST, issued 02-Aug-2022 by Co-Diagnostics over PR Newswire, we are advised by the company that...
Jul 27, 2022

Co-Diagnostics, Inc. to Participate in Yale University SalivaDirect™ Conference Held July 28-29 in Chicago

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Jul 26, 2022

Co-Diagnostics, Inc. to Announce Expansion of OEM Agreement with Bio Molecular Systems at AACC

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Jul 20, 2022

Co-Diagnostics, Inc. to Host Booth at AACC Held July 24-28 in Chicago

The Company will also be providing an update to its distributors and other customers on July 26 at 11 am CT. SALT LAKE CITY, July 20, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the...
Jul 11, 2022

Co-Diagnostics, Inc. Announces Shipment of Monkeypox Virus Test

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
Jun 28, 2022

Co-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual Conference

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Jun 15, 2022

Co-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Jun 9, 2022

Co-Diagnostics, Inc. to Host Booth at MEDEXPO Africa 2022 in Nairobi, Kenya on June 9-11

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
May 26, 2022

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
May 19, 2022

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
May 12, 2022

Co-Diagnostics Reports Solid First Quarter 2022 Financial Results

Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY, May 12, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular...
May 3, 2022

Co-Diagnostics, Inc. to Host Booth at Medical Fair Brasil 2022 in São Paulo on May 3-6

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Apr 28, 2022

CO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first...
Apr 22, 2022

Co-Diagnostics, Inc. to Host Booth at ECCMID 2022 in Lisbon, Portugal on April 23-26

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Apr 19, 2022

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis C Viral Load Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Mar 24, 2022

Co-Diagnostics Reports Full Year 2021 Financial Results

Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY'22 SALT LAKE CITY, March 24, 2022 /PRNewswire/ -- Co-Diagnostics, Inc....
Mar 22, 2022

Co-Diagnostics, Inc. to Present at MarketsandMarkets Conference on March 23-24 in London, England

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Mar 17, 2022

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce...
Mar 15, 2022

Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its...
Mar 14, 2022

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 EARNINGS RELEASE DATE AND WEBCAST

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth...
Feb 17, 2022

Co-Diagnostics, Inc. to Sponsor and Present at Molecular Med Tri-Con 2022

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Feb 10, 2022

Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Feb 3, 2022

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Jan 21, 2022

Co-Diagnostics, Inc. to Host Booth at Medlab Middle East 2022 in Dubai on January 24-27

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Jan 13, 2022

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Jan 10, 2022

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 BioConnect Virtual Conference on January 10-13

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Dec 31, 2021

Co-Diagnostics, Inc. Announces Completion of the Acquisition of all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...
Dec 22, 2021

Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...
Dec 7, 2021

Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Nov 29, 2021

Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, reported today that none of...
Nov 15, 2021

Co-Diagnostics, Inc. to Host Booth at MEDICA 2021 Trade Fair in Düsseldorf, Germany

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Nov 11, 2021

Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results

Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the...
Nov 4, 2021

Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom

Company's validated test available in the UK following implementation of UKHSA CTDA Regulations

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2...
Oct 28, 2021

Co-Diagnostics, Inc. Announces Third Quarter 2021 Earnings Release Date And Webcast

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third...
Oct 6, 2021

Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for Dengue/Chikungunya Multiplex Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Sep 27, 2021

Co-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28

In addition to hosting a booth to promote its existing diagnostics products at the conference, the Company will also hold a press conference to introduce its upcoming at-home and point-of-care PCR device

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Sep 23, 2021

Co-Diagnostics, Inc. Announces Corporate Rebranding Following Period of Transformative Growth and Expansion

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Sep 21, 2021

Co-Diagnostics, Inc. to Present at ACTC Liquid Biopsy Conference in Kalamata, Greece

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Sep 21, 2021

Co-Diagnostics, Inc. Logix Smart™ ABC Test Authorized for Use in Mexico

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza...
Sep 20, 2021

Co-Diagnostics, Inc. to Present at Sidoti Virtual Investor Conference

Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian...
Sep 16, 2021

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Sep 13, 2021

Co-Diagnostics, Inc. CEO to Participate in Panel Discussion with Scott Gottlieb, M.D., at H.C. Wainwright 2021 Annual Global Investor Conference

Company CEO and CFO will also be conducting a presentation that will be available on-demand

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Sep 8, 2021

Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy

Peer-reviewed results describe the Company's test being used to confirm the presence of the virus on community waste, including mutated strains

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test...
Aug 23, 2021

Co-Diagnostics, Inc. To Present At 13th Next Generation Dx Summit In Washington, D.C.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Aug 12, 2021

Co-Diagnostics Reports Strong Second Quarter 2021 Financial Results

Solid quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the...
Aug 4, 2021

Co-Diagnostics, Inc. Announces Second Quarter 2021 Earnings Release Date And Webcast

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second...
Jul 22, 2021

Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its...
Jun 18, 2021

Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™...
Jun 15, 2021

Co-Diagnostics, Inc. to Present at Upcoming Technology and Health Research Conferences

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
May 13, 2021

Co-Diagnostics Reports First Quarter 2021 Financial Results

Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million and diluted EPS of $0.26

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the...
May 4, 2021

Co-Diagnostics, Inc. Announces First-Quarter 2021 Earnings Release Date and Webcast

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its...
Apr 29, 2021

Co-Diagnostics, Inc. and Partner CRL to Discuss Saliva Testing and Future Applications of PCR in 360Dx Webinar

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be...
Apr 28, 2021

Co-Diagnostics, Inc. JV CoSara Diagnostics Recognized for Work Combating COVID-19 Surge in India

Times of India article highlights CoSara's tireless efforts to increase manufacturing of COVID-19 tests in response to deadly wave of infections

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Indian...
Apr 20, 2021

Co-Diagnostics, Inc. Test Performance Demonstrated by Australian Researchers in Peer-Reviewed Publication

Paper published in the Journal of Medical Microbiology utilizes Company's test in rapidly deployable mobile molecular diagnostics

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test...
Mar 31, 2021

Co-Diagnostics, Inc. CEO Discusses Company Strategy for the Future with Yahoo! Finance

The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, appeared yesterday on Yahoo! Finance to...
Mar 25, 2021

Co-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results

Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the...
Mar 18, 2021

Co-Diagnostics, Inc. Announces Fourth-Quarter and Full-Year 2020 Earnings Release Date and Webcast

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its...
Mar 16, 2021

Co-Diagnostics Invited to Present at Maxim Group LLC Emerging Growth Virtual Conference

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Mar 10, 2021

Co-Diagnostics to Present Point-of-Care and At Home Testing Platform at Infectious Disease Diagnostics Virtual Conference

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Mar 8, 2021

Co-Diagnostics to Discuss Recent Company Advances at H.C. Wainwright Global Life Sciences Virtual Conference

Co-Diagnostics, Inc. (NASDAQ-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Mar 2, 2021

Co-Diagnostics New Rapid PCR Point-of-Care and at Home Testing Platform to Detect Covid-19 and Other Diseases Using CoPrimer™ Technology

Proprietary platform includes countertop device being developed for Co-Diagnostics by world experts in rapid PCR

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the development of a new...
- Photos 1
Feb 25, 2021

Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based COVID-19 PCR Test Through Walgreens Find Care®

Clinical Reference Laboratory's FDA-authorized saliva-based PCR test uses technology developed by Co-Diagnostics to detect SARS-CoV-2

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that laboratory partner Clinical...
Feb 23, 2021

Co-Diagnostics, Inc. Announces New Chief Financial Officer

Company also elevates in-house Senior VP of Biochemistry to Chief Scientific Officer

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is pleased to welcome Brian Brown
Feb 16, 2021

Co-Diagnostics, Inc. to Present on Direct Saliva Testing Technology at Molecular Med Tri-Con

Company believes direct saliva to play a key role in high throughput, point of care, and at home applications

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be presenting on direct...
Jan 28, 2021

Co-Diagnostics Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test

The Company's Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test is designed to reduce sample processing time and cost by eliminating the extraction process

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Jan 7, 2021

Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Jan 6, 2021

Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that,...
Dec 22, 2020

Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform

Proprietary Company design process facilitates rapid response in detecting mutation of a new coronavirus strain circulating in the UK

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...
Dec 14, 2020

Co-Diagnostics Announces Milestone of Over 10 Million COVID-19 Tests Sold

Company anticipates Q4 revenue will significantly exceed previous quarter

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...
Nov 25, 2020

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Nov 17, 2020

Co-Diagnostics, Inc. Receives CE Markings for "ABC" and SARS-CoV-2 2-Gene Multiplex Tests

New tests expand global reach of Company COVID-19 test menu

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC...
Nov 16, 2020

Co-Diagnostics, Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07

Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the...
Nov 11, 2020

Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company...
Nov 10, 2020

Co-Diagnostics, Inc. Announces Q3 2020 Earnings Release Date and Earnings Webcast

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its...
Nov 2, 2020

Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following the...
Oct 2, 2020

Co-Diagnostics, Inc. Logix Smart Kit to be Used with Newly Authorized Saline Oral Rinse Collection

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Access Genetics, LLC dba...
Sep 24, 2020

Co-Diagnostics, Inc. Provides Update on "ABC" Test for Influenza A, Influenza B, and COVID-19

Company expects to begin taking orders from US CLIA labs first week of October 2020

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ ABC Test...

Show per page